Diese Studie enthält eine ausreichend große Teilnehmerzahl. Sie können sich hierfür nicht mehr an- oder abmelden.

Inflammotory diseases

Ort der Studie

Nederland (1)
Groningen

Geschlecht Beides
Alter von 18 bis 55
Rauchgewohnheiten Nicht
BMI von 18 bis 30
Berechnen Sie Ihren BMI hier

Study of a new compound that is being developed for the treatment chronic inflammatory diseases (such as rheumatoid arthritis)

Besonderheiten (auf Englisch)

You are a healthy male or female.
You are between 18 and 55 years old.
You do not smoke.
Your Body Mass Index (BMI) is between 18 and 30 kg/m2.
You can only participate in this study if you have not participated in another study within 12 weeks prior to the first drug administration in this study.
As a male you are only allowed to participate in this study if:
- You will use a condom and your fertile female partner uses an intrauterine device (including copper ones) or a hormonal contraceptive;
- or you were vasectomized;
- or your female partner is at least 12 months postmenopausal (without menstrual periods) or surgically sterilized;
- or you are completely abstinent (not sexually active) during the study in accordance with your lifestyle;
- or you are only sexual active with a male.
As a female you are only allowed to participate in this study if:
- You have been postmenopausal and you have not menstruated for a period of 12 months before screening
- You were surgical sterilized (both ovaries or fallopian tubes have been removed, or removal of the uterus)
To determine if you are eligible to participate in this study, you will undergo a medical screening in Groningen. This will take place within 6 weeks before the clinical start.

Vergütung (auf Englisch)

You will receive a gross compensation of €2.289,- for full participation in Group 2a or 2b..

Travel expenses will be reimbursed based on the distance traveled (€0.19 net per kilometer) with a minimum of €12 and a maximum of €160 (840 kilometers) per round trip, irrespective of the method of transportation.

Periode und Studie (auf Englisch)

For Group 2a and 2b, the study consists of 1 period in which you will stay in our research facility in Groningen for 14 days (13 nights).

Approximately 12 to 16 days after the last administration of the compound, a follow-up visit will take place.

Please note: These are the currently planned dates; however, these may be subject to change.

Group 2a	14 days stay 26 Oct 2020 up to and including 8 Nov 2020	follow-up by appointment
Group 2b	14 days stay 7 Nov 2020 up to and including 20 Nov 2020	follow-up by appointment
Group 2c	14 days stay 11 Nov 2020 up to and including 24 Nov 2020	follow-up by appointment
Groep 2d	14 days stay 8 Dec 2020 up to and including 21 Dec 2020	follow-up by appointment

Inflammotory diseases

Besonderheiten (auf Englisch)

Vergütung (auf Englisch)

Periode und Studie (auf Englisch)

Group 2a

14 days stay

follow-up

Group 2b

14 days stay

follow-up

Group 2c

14 days stay

follow-up

Groep 2d

14 days stay

follow-up